Adage Capital Partners LP Form 8.3 - Horizon Therapeutics PLC (2544N)
September 21 2023 - 8:04AM
UK Regulatory
TIDMTTM TIDMHZNP
RNS Number : 2544N
Adage Capital Partners LP
21 September 2023
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note Adage Capital Partners GP, L.L.C.
1)
Company dealt in Horizon Therapeutics PLC
=================================
Class of relevant security US$0.0001 ordinary shares
to which the dealings being
disclosed relate (Note 2)
=================================
Date of dealing 20(th) of September 2023
=================================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
======= ==== ==== ========= ==== ====
(1) Relevant securities 3,145,815 1.37%
=================== =====================
(2) Derivatives (other
than options)
=================== =====================
(3) Options and agreements
to purchase/sell
=================== =====================
Total
=================== =====================
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
======= ==== ==== ========= ==== ====
(1) Relevant securities
=================== =====================
(2) Derivatives (other
than options)
=================== =====================
(3) Options and agreements
to purchase/sell
=================== =====================
Total
=================== =====================
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant Price per unit
securities (Note 5)
Sale 50,000 115.542
=========================== ====================
Sale 50,000 115.545
=========================== ====================
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, (Note 6) securities unit
e.g. CFD (Note 7) (Note 5)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding between
the person disclosing and any other person relating to the voting
rights of any relevant securities under any option referred to
on this form or relating to the voting rights or future acquisition
or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be
stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 21(st) of September 2023
Contact name Chris Palmer
========================
Telephone number 617-867-2514
========================
If a connected EFM, name
of offeree/offeror with
which connected
========================
If a connected EFM, state
nature of connection (Note
10)
========================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ITPLFLFLXKLBBBF
(END) Dow Jones Newswires
September 21, 2023 08:04 ET (12:04 GMT)
Amgen (LSE:0R0T)
Historical Stock Chart
From Oct 2024 to Nov 2024
Amgen (LSE:0R0T)
Historical Stock Chart
From Nov 2023 to Nov 2024
